<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04296604</url>
  </required_header>
  <id_info>
    <org_study_id>2014P001428</org_study_id>
    <nct_id>NCT04296604</nct_id>
  </id_info>
  <brief_title>Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations</brief_title>
  <official_title>Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the current study, the investigators aim to understand the role of transcranial direct
      current stimulation (tDCS) in improving executive function across neuropsychiatric
      populations known to have deficits in this cognitive domain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the current study, the investigators aim to understand the role of transcranial direct
      current stimulation (tDCS) in improving executive function across neuropsychiatric
      populations known to have deficits in this cognitive domain. The investigators will select 8
      relevant diagnostic categories: traumatic brain injury, major depressive disorder, bipolar
      disorder, schizophrenia, attention deficit hyperactivity disorder, borderline personality
      disorder and substance use disorder. The study will also include a cohort of healthy controls
      for comparison.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in N-Back Task</measure>
    <time_frame>Baseline to Post-Treatment, 1 Week</time_frame>
    <description>Working Memory Task</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Flanker Task</measure>
    <time_frame>Baseline to Post-Treatment, 1 Week</time_frame>
    <description>Attention and Inhibitory Control Task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multi-Source Interference with International Affective Picture System Task</measure>
    <time_frame>Baseline to Post-Treatment, 1 Week</time_frame>
    <description>Cognitive Control During Emotional Regulation Task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Delayed Discounting Task</measure>
    <time_frame>Baseline to Post-Treatment, 1 Week</time_frame>
    <description>Decision-Making Task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Stop Signal Task</measure>
    <time_frame>Baseline to Post-Treatment, 1 Week</time_frame>
    <description>Ability to Inhibit a Response Task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Iowa Gambling Task</measure>
    <time_frame>Baseline to Post-Treatment, 1 Week</time_frame>
    <description>Risk-Taking Task</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <condition>Major Depressive Disorder</condition>
  <condition>Bipolar Disorder</condition>
  <condition>Schizophrenia</condition>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <condition>Borderline Personality Disorder</condition>
  <condition>Substance Use Disorders</condition>
  <arm_group>
    <arm_group_label>Traumatic Brain Injury</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group consists of individuals diagnosed with traumatic brain injury. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Major Depressive Disorder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group consists of individuals diagnosed with major depressive disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bipolar Disorder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group consists of individuals diagnosed with bipolar disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Schizophrenia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group consists of individuals diagnosed with schizophrenia. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Attention Deficit Hyperactivity Disorder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group consists of individuals diagnosed with attention deficit hyperactivity disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Borderline Personality Disorder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group consists of individuals diagnosed with borderline personality disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Substance Use Disorder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group consists of individuals diagnosed with substance use disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group consists of individuals diagnosed with healthy controls. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial Direct Current Stimulation</intervention_name>
    <description>In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.</description>
    <arm_group_label>Attention Deficit Hyperactivity Disorder</arm_group_label>
    <arm_group_label>Bipolar Disorder</arm_group_label>
    <arm_group_label>Borderline Personality Disorder</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>Major Depressive Disorder</arm_group_label>
    <arm_group_label>Schizophrenia</arm_group_label>
    <arm_group_label>Substance Use Disorder</arm_group_label>
    <arm_group_label>Traumatic Brain Injury</arm_group_label>
    <other_name>tDCS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Male and female outpatients 18-65 years of age

          2. A diagnosis of traumatic brain injury, major depressive disorder, bipolar disorder,
             schizophrenia, attention deficit hyperactivity disorder, borderline personality
             disorder and substance use disorders meeting the Diagnostic and Statistical Manual of
             Mental Disorders, Fifth Edition (DSM-5) criteria.

        Exclusion Criteria

          1. Contraindication to tDCS: history or epilepsy, metallic implants in the head and neck,
             brain stimulators, vagus nerve stimulators, shunts, pacemakers, pregnancy.

          2. Active substance dependence (except for tobacco and cannabis).

          3. Pregnant or nursing females.

          4. Inability to participate in testing procedures.

          5. Additional exclusion criteria for healthy controls:

               1. Diagnosis of psychiatric of neurological disorder

               2. Ongoing treatment with any psychotropic medications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joan Camprodon, MD, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joan Camprodon, MD, PhD, MPH</last_name>
    <phone>6177265348</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patricia Cirillo, MD, PhD</last_name>
    <phone>6177243217</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Funes, MS</last_name>
      <phone>617-724-8780</phone>
      <email>cjfunes@mgh.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 28, 2020</study_first_submitted>
  <study_first_submitted_qc>March 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2020</study_first_posted>
  <last_update_submitted>March 6, 2020</last_update_submitted>
  <last_update_submitted_qc>March 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Joan A Camprodon, MD MPH PhD</investigator_full_name>
    <investigator_title>Chief of Division of Neuropsychiatry, Director of TMS Clinic, Director of Lab for Neuropsychiatry and Neuromodulation</investigator_title>
  </responsible_party>
  <keyword>Transcranial Direct Current Stimulation</keyword>
  <keyword>Executive Function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Personality Disorders</mesh_term>
    <mesh_term>Borderline Personality Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

